Catalyst
Slingshot members are tracking this event:
Seattle Genetics to report phase 1 clinical data from ASG-15ME and ASG-22ME at the ASCO annual meeting being held June 3 to 7, 2016. These programs are in development in collaboration with Astellas for solid tumors, notably bladder cancer.
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 06, 2016
Occurred Source:
http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2175252
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Asg-15me, Asg-22me, Asco, Bladder Cancer, Solid Tumors
